Cellbion Co

Cellbion Co FCF/Debt

The Free Cash Flow to Debt Ratio of Cellbion Co (308430.KQ) as of Nov 2, 2026 is -722.48 %. In the previous year, Free Cash Flow to Debt Ratio was -240.65 % — a change of 200.22% (lower).

FCF/Debt

-722.48 %

YoY

200.22%

Last updated:

Free Cash Flow to Debt Ratio of Cellbion Co is 2025 -722.48 % . Free Cash Flow to Debt Ratio of Cellbion Co was 2024 -240.65 % . It decreases by 200.22% lower compared to the previous year.

The Cellbion Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2022
-185.97 KRW
Jan 1, 2023
-284.45 KRW
Jan 1, 2024
-240.65 KRW
Jan 1, 2025
-722.48 KRW
The Cellbion Co FCF/Debt history
YEARFCF/DebtYoY
-722.48 %+200.22%
-240.65 %-15.40%
-284.45 %+52.96%
-185.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellbion Co Stock analysis

What does Cellbion Co do? Cellbion Co Ltd generates revenue through the manufacture and sale of pharmaceuticals, including innovative diagnostic and therapeutic new drugs developed by the company. The firm also sells generic prescription drugs and provides contract development and manufacturing organization (CDMO) services for clinical trial drugs. Additionally, the company produces cosmetic products under its own brand. The primary customers are healthcare providers, hospitals, and pharmaceutical companies seeking drug development and manufacturing solutions. The company's product segments include pharmaceuticals, generic prescription drugs, CDMO services, and cosmetics. Key buyers are healthcare institutions, pharmaceutical firms, and consumers purchasing cosmetics. Cellbion Co Ltd targets the Korean market with its domestic operations, focusing on both B2B and B2C segments through its diverse product portfolio. Cellbion Co Ltd's revenue streams are derived from the sale of pharmaceuticals, generic drugs, CDMO services, and cosmetic products. The company's business model emphasizes innovation in drug development alongside traditional pharmaceutical manufacturing, with a focus on serving the domestic Korean healthcare sector and expanding its CDMO capabilities for global clinical trials. Cellbion Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellbion Co stock

Free Cash Flow to Debt Ratio of Cellbion Co is -722.48 % in 2025.

Free Cash Flow to Debt Ratio of Cellbion Co changed from -240.65 % to -722.48 %, representing a 200.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Cellbion Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Cellbion Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cellbion Co

All Key Metrics — Cellbion Co